The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation
Alterations of the gut microbiota may cause dysregulated mucosal immune responses leading to the onset of inflammatory bowel diseases (IBD) in genetically susceptible hosts. Restoring immune homeostasis through the normalization of the gut microbiota is now considered a valuable therapeutic approach...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/9/5/1234 |
| _version_ | 1797567825734270976 |
|---|---|
| author | Chiara Amoroso Federica Perillo Francesco Strati Massimo Fantini Flavio Caprioli Federica Facciotti |
| author_facet | Chiara Amoroso Federica Perillo Francesco Strati Massimo Fantini Flavio Caprioli Federica Facciotti |
| author_sort | Chiara Amoroso |
| collection | DOAJ |
| description | Alterations of the gut microbiota may cause dysregulated mucosal immune responses leading to the onset of inflammatory bowel diseases (IBD) in genetically susceptible hosts. Restoring immune homeostasis through the normalization of the gut microbiota is now considered a valuable therapeutic approach to treat IBD patients. The customization of microbe-targeted therapies, including antibiotics, prebiotics, live biotherapeutics and faecal microbiota transplantation, is therefore considered to support current therapies in IBD management. In this review, we will discuss recent advancements in the understanding of host−microbe interactions in IBD and the basis to promote homeostatic immune responses through microbe-targeted therapies. By considering gut microbiota dysbiosis as a key feature for the establishment of chronic inflammatory events, in the near future it will be suitable to design new cost-effective, physiologic, and patient-oriented therapeutic strategies for the treatment of IBD that can be applied in a personalized manner. |
| first_indexed | 2024-03-10T19:47:58Z |
| format | Article |
| id | doaj.art-c294139df175420fada592c509b962d9 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T19:47:58Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-c294139df175420fada592c509b962d92023-11-20T00:41:03ZengMDPI AGCells2073-44092020-05-0195123410.3390/cells9051234The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal InflammationChiara Amoroso0Federica Perillo1Francesco Strati2Massimo Fantini3Flavio Caprioli4Federica Facciotti5Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, ItalyDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, ItalyDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, ItalyGastroenterology Unit, Duilio Casula Hospital, AOU Cagliari, 09042 Cagliari, ItalyDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, 20135 Milan, ItalyDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, ItalyAlterations of the gut microbiota may cause dysregulated mucosal immune responses leading to the onset of inflammatory bowel diseases (IBD) in genetically susceptible hosts. Restoring immune homeostasis through the normalization of the gut microbiota is now considered a valuable therapeutic approach to treat IBD patients. The customization of microbe-targeted therapies, including antibiotics, prebiotics, live biotherapeutics and faecal microbiota transplantation, is therefore considered to support current therapies in IBD management. In this review, we will discuss recent advancements in the understanding of host−microbe interactions in IBD and the basis to promote homeostatic immune responses through microbe-targeted therapies. By considering gut microbiota dysbiosis as a key feature for the establishment of chronic inflammatory events, in the near future it will be suitable to design new cost-effective, physiologic, and patient-oriented therapeutic strategies for the treatment of IBD that can be applied in a personalized manner.https://www.mdpi.com/2073-4409/9/5/1234inflammatory bowel diseasesgut microbiomelive biotherapeutic productsFMT |
| spellingShingle | Chiara Amoroso Federica Perillo Francesco Strati Massimo Fantini Flavio Caprioli Federica Facciotti The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation Cells inflammatory bowel diseases gut microbiome live biotherapeutic products FMT |
| title | The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation |
| title_full | The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation |
| title_fullStr | The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation |
| title_full_unstemmed | The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation |
| title_short | The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation |
| title_sort | role of gut microbiota biomodulators on mucosal immunity and intestinal inflammation |
| topic | inflammatory bowel diseases gut microbiome live biotherapeutic products FMT |
| url | https://www.mdpi.com/2073-4409/9/5/1234 |
| work_keys_str_mv | AT chiaraamoroso theroleofgutmicrobiotabiomodulatorsonmucosalimmunityandintestinalinflammation AT federicaperillo theroleofgutmicrobiotabiomodulatorsonmucosalimmunityandintestinalinflammation AT francescostrati theroleofgutmicrobiotabiomodulatorsonmucosalimmunityandintestinalinflammation AT massimofantini theroleofgutmicrobiotabiomodulatorsonmucosalimmunityandintestinalinflammation AT flaviocaprioli theroleofgutmicrobiotabiomodulatorsonmucosalimmunityandintestinalinflammation AT federicafacciotti theroleofgutmicrobiotabiomodulatorsonmucosalimmunityandintestinalinflammation AT chiaraamoroso roleofgutmicrobiotabiomodulatorsonmucosalimmunityandintestinalinflammation AT federicaperillo roleofgutmicrobiotabiomodulatorsonmucosalimmunityandintestinalinflammation AT francescostrati roleofgutmicrobiotabiomodulatorsonmucosalimmunityandintestinalinflammation AT massimofantini roleofgutmicrobiotabiomodulatorsonmucosalimmunityandintestinalinflammation AT flaviocaprioli roleofgutmicrobiotabiomodulatorsonmucosalimmunityandintestinalinflammation AT federicafacciotti roleofgutmicrobiotabiomodulatorsonmucosalimmunityandintestinalinflammation |